PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer
Status:
Recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of PD-1 inhibitor and
anlotinib combined with multimodal radiotherapy for the second-line treatment of recurrent or
metastatic anaplastic thyroid cancer.